Basic Study

Nuclear magnetic resonance-based metabolomics and metabolic pathway networks from patient-matched esophageal carcinoma, adjacent noncancerous tissues and urine

Jia-Hao Liang, Yan Lin, Ting Ouyang, Wan Tang, Yao Huang, Wei Ye, Jia-Yun Zhao, Zhe-Ning Wang, Chang-Chun Ma

ORCID number: Jia-Hao Liang (0000-0002-6288-6288); Yan Lin (0000-0002-8284-9029); Ting Ouyang (0000-0003-4710-3069); Wan Tang (0000-0003-0404-1494); Yao Huang (0000-0001-5616-7828); Wei Ye (0000-0003-1459-0135); Jia-Yun Zhao (0000-0003-2446-2288); Zhe-Ning Wang (0000-0003-3754-0943); Chang-Chun Ma (0000-0002-5389-4250).

Author contributions: Lin Y conceived and designed the experiments; Liang JH and Lin Y contributed to NMR data acquisition; Liang JH, Ouyang T, Tang W and Huang Y analyzed the data; Lin Y wrote the paper; Ye W, Zhao JY and Wang ZN contributed to sample preparation; all authors approved the final version of the manuscript for publication.

Supported by the National Natural Science Foundation of China, No. 81471729 and No. 81101102; the Science and Technology and Planning Project of Guangdong Province, No. 2016A020216025; the Research Award Fund for Outstanding Young Teachers in Higher Education Institutions, Guangdong Province, No. YQ2015245; the National Natural Science Foundation of Guangdong Province, No. S201101004973; the Department of Education of Guangdong Province, No. 2017KTSCX071.

Institutional review board statement: This study was approved by the institutional review boards of the participating centers.

Abstract

BACKGROUND

Several studies have demonstrated a correlation between esophageal cancer (EC) and perturbed urinary metabolomic profiles, but none has described the correlation between urine metabolite profiles and those of the tumor and adjacent esophageal mucosa in the same patient.

AIM

To investigate how urinary metabolic phenotypes were linked to the changes in the biochemical landscape of esophageal tumors.

METHODS

Nuclear magnetic resonance-based metabolomics were applied to esophageal tumor tissues and adjacent normal mucosal tissues alongside patient-matched urine samples.

RESULTS

Analysis revealed that specific metabolite changes overlapped across both metrics, including glucose, glutamate, citrate, glycine, creatinine and taurine, indicating that the networks for metabolic pathway perturbations in EC, potentially involved in but not limited to disruption of fatty acid metabolism, glucose and glycolytic metabolism, tricarboxylic acid cycle and glutaminolysis. Additionally, changes in most urinary biomarkers correlated with changes in biomarker candidates in EC tissues, implying enhanced energy production for rapid cell proliferation.
Esophageal cancer (EC) is the eighth most common type of malignant tumor and the sixth leading cause of cancer-related death worldwide[1]. Identifying cancer-related biomarkers of EC is essential for its diagnosis and therapeutic intervention in the early stage, which in turn will significantly increase patient survival. While there are a few diagnostic/screening techniques, such as upper gastrointestinal endoscopy, endoscopy-based balloon cytology, and serum carcinoembryonic antigen (commonly known as CEA) test, high-throughput and sensitive molecular tools are required to elucidate specific disease biomarkers for optimal disease management. Metabolomics, in which the global changes of small molecular weight metabolites in a given biological specimen are investigated, has considerable potential to identify useful biomarkers, thereby stratifying subjects into disease or nondiseased categories[2,3]. Proton nuclear magnetic resonance (1H-NMR) spectroscopy is a well-established, robust, noninvasive and reproducible method for quantifying metabolic profiles[4,5], and it has several advantages over other analytical techniques, such as liquid chromatography mass spectroscopy and gas chromatography mass spectroscopy, including nondestructive analysis of samples, minimal sample preparation, and the ability to detect multiple metabolites within a single experiment[6,7]. NMR data combined with multivariate statistical analysis, such as orthogonal partial least squares discriminant analysis (OPLS-DA), which can be utilized for disease classification (through the use of score plots) and biomarker detection (through the use of loading plots), allow for the identification of potential biomarkers in biological specimens and improve the ability to identify specific metabolic pathways and networks associated with the disease process.

Urine is a biological fluid commonly used by NMR-based metabolomics[8,9] because it is easily collected in large volumes with noninvasive procedures and may provide substantial diagnostic information for many cancer types[10-12]. Biomarkers in urine may be derived from cell apoptosis, glomerular filtration of blood plasma, cell sloughing, epithelial cell secretion of exosomes, and other processes[13]. Several NMR spectroscopy-based metabolomic studies have reported that metabolite compositions of urine samples from EC patients differ from those of healthy controls (HCs)[14,15]. However, little is known about the systemic mechanistic link between esophageal tissues and urine, owing to the invasiveness of tissue sampling and sensitivity of the urinary metabolome to factors such as environment, food and genetic composition.

The aim of this research was to profile parallel metabolites of EC tissues and adjacent noncancerous tissues, and to compare the urinary metabolome profiles of EC patients with those of healthy controls using multivariate statistical methods and NMR-based metabolomics. The results of this study provide evidence for distinct metabolic signatures and metabolic pathway disturbances between the tumor tissues and urine of EC patients, and changes in the urinary metabolic signature reflect reprogramming of the aforementioned metabolic pathways in EC tissues. Further investigation is needed to validate these initial findings using larger samples and to establish the underlying mechanism of EC progression.
MATERIALS AND METHODS

Patient recruitment and sample collection
This study was approved by the Ethics Committee of Shantou University Medical College. Written informed consent was obtained from each subject prior to participation. Early-morning midstream urine samples were collected preoperatively from 41 EC patients and 40 HCs between August 2015 and October 2016 at the Second Affiliated Hospital of Shantou University Medical College. EC patients were diagnosed by microscopy, biopsy, or surgical resection, and the disease stage was determined according to the American Joint Committee on Cancer (AJCC) staging system for esophageal tumors: Stage I/II, 15 patients; stage III, 11 patients; stage IV, 15 patients. Each urine sample was mixed with 50 μL sodium azide preservative and stored at −80 °C until further analysis. Patient-matched EC tissues and their corresponding adjacent noncancerous tissues (~5 cm away from the tumor margin) were collected from 20 EC patients and immediately stored at −80 °C until NMR analysis. Exclusion criteria for all participants included use of antibiotics, nonsteroidal anti-inflammatory drugs, statins, or probiotics within 2 mo of study participation. Additional exclusion criteria for EC patients included chemotherapy or radiotherapy prior to surgery. The demographic and clinical characteristics of the EC patients and controls are summarized in Table 1.

Urine sample preparation
Frozen urine samples were thawed at room temperature and mixed to suspend any settled precipitate. After adding 300 μL PBS/D$_2$O buffer (0.1 M, pH 7.4) to 600 μL of each urine sample, the mixture was homogenized by vortexing for 60 s and then centrifuged at 8000 rpm for 10 min. Subsequently, a volume of 500 μL of the supernatant was transferred into an Eppendorf vial, to which 50 μL of a stock solution of sodium (3-trimethylsilyl)-2, 2, 3, 3-tetradeuteriopropionate (TSP)/D$_2$O was added, using a chemical shift reference (0.0 ppm) for spectral alignment. Finally, the resulting mixture was centrifuged at 10000 rpm for 5 min, and 500 μL of the prepared sample was transferred into a 5-mm high-resolution NMR tube for $^1$H-NMR analysis.

Tissue sample preparation
The frozen tissue samples weighed ~300 mg and were thawed and cut into small pieces at room temperature. After adding 1.8 mL mixture containing 0.6 mL distilled water (2 mL/g tissue) and 1.2 mL methanol (4 mL/g tissue), the resulting mixture was homogenized at 16000 rpm for 80 s. After homogenization, the mixture was added to chloroform (4 mL/g tissue) and distilled water (4 mL/g tissue) and vortexed for 60 s. The suspension was then left on ice for 15 min and centrifuged at 2000 rpm for 5 min to facilitate separation of the liquid layers. The resulting supernatant was evaporated under a stream of nitrogen and then dried under vacuum for a minimum of 18 h. Subsequently, the lyophilized powder was redissolved with 550 μL PBS/D$_2$O buffer (0.1 mol/L, pH 7.4), to which 50 μL of a stock solution of TSP/D$_2$O was added. After homogenization and centrifugation at 10000 rpm for 5 min, 500 μL supernatant was transferred into a 5-mm high-resolution NMR tube for $^1$H-NMR analysis.

$^1$H-NMR analysis
All samples were detected by a Bruker AVII 400 MHz NMR spectrometer (Bruker Biospin, Germany) operating at a $^1$H frequency of 400.13 MHz. Magnetic field homogeneity was optimized by gradient or manual shimming prior to acquisition. The temperature was maintained at 298 K and lock performed on the D$_2$O signal. $^1$H NMR spectra of urine samples were obtained using a 1D nuclear Overhauser enhancement spectroscopy pulse sequence [RD-90°-tl-90°-tm-90°- ACQ], with the following acquisition parameters: Recycle delay (RD) 1.5 s; tl 3 μs; mixing time, tm 100 ms; 90° pulse width 7.3 μs; number of scans (NS) 256; number of points, TD 32768; spectral width (SW) 8012.82 Hz; acquisition time (AQ) 2.04 s. Water suppression was achieved by irradiation of the water peak during RD and tm. Esophageal tissue $^1$H NMR spectra were recorded using a standard (1D) Carr–Purcell–Meiboom–Gill pulse sequence with the following acquisition parameters: number of dummy scans 4; RD
Table 1 Summary of clinical and demographic features for study subjects and tumor characteristics

|                  | EC   | HC   | \( \chi^2 \) | \( P \) value |
|------------------|------|------|--------------|---------------|
| Subjects, \( n \) | 41   | 40   |              |               |
| Age (median, range), yr | 60, 39-77 | 59, 28-78 | 6.77        | 0.12          |
| Sex              |      |      |              |               |
| Male             | 31   | 19   |              |               |
| Female           | 10   | 21   |              |               |
| Cancer stage     |      |      |              |               |
| Stage I/II       | 15   |      |              |               |
| Stage III        | 11   |      |              |               |
| Stage IV         | 15   |      |              |               |
| CEA, ng/mL       |      |      |              |               |
| Positive         | 2    |      |              |               |
| Negative         | 31   |      |              |               |
| Not measured     | 8    |      |              |               |
| CA 19-9, U/mL    |      |      |              |               |
| Positive         | 2    |      |              |               |
| Negative         | 18   |      |              |               |
| Not measured     | 21   |      |              |               |
| Location         |      |      |              |               |
| Cervical         | 1    |      |              |               |
| Upper thoracic   | 5    |      |              |               |
| Middle thoracic  | 24   |      |              |               |
| Lower thoracic   | 11   |      |              |               |
| Symptoms         |      |      |              |               |
| Dysphagia        | 40   |      |              |               |
| Gastroesophageal reflux | 27 |      |              |               |

EC: Esophageal cancer; HC: Healthy control; CA 19-9: Carbohydrate antigen 19-9; CEA: Carcinoembryonic antigen.

70 ms; 90° pulse width 10 μs; NS 64; TD 65536; SW 8012 Hz; AQ 4.09 s.

1H NMR spectral data processing

All free induction decays from 1D 1H-NMR of the tissues and urine samples were multiplied by a 0.3 Hz exponential line broadening prior to Fourier transformation. 1H-NMR spectra were then corrected for phase and baseline distortion and calibrated to TSP at 0.0 ppm by using MestReNova software (version 8.1.0, Mestrelab Research, Santiago de Compostella, Spain). To reduce the complexity of the NMR data, the spectral range from 0.8 to 9.0 ppm was segmented into buckets with the equal width of 0.004 ppm. The region of 5.5-4.5 ppm was discarded to eliminate imperfect water suppression. Each bucket was internally normalized to the total integral of the spectrum prior to pattern recognition analysis, to eliminate the dilution or bulk mass differences among samples due to the different sample weight.

Pattern recognition analysis and cross validation

To maximize class discrimination between EC patient and HC urine samples, as well as between EC tissues and their corresponding noncancerous tissues, multivariate data analysis was applied to the 1H-NMR spectral data according to previously published and accepted methods\(^\text{[6,7]}\). The normalized NMR spectral data sets were unit variance scaled and analyzed using the SIMCA-P+ program (version 14.1, Umetrics AB; Umea, Sweden). OPLS-DA was applied to the analysis of 1H-NMR spectral data to optimize the separation between experimental groups. The model quality was evaluated with the \( R^2 \)Y and \( Q^2 \) values, reflecting the explained fraction of variance and the model predictability. \( R^2 \)Y scores ranged between 0 and 1 and \( Q^2 \) scores between negative and 1, where a \( R^2 \)Y score of 1 demonstrated that the model explained 100% of variance, and a \( Q^2 \) score closer to 1 indicated higher reliability of the prediction in the cross-validation procedure. Validation of the OPLS-DA model was also performed by means of a permutation test (400 times). The \( R^2 \)Y in the permuted plot described
how well the data fitted with the derived model, whereas $Q^2$ described the predictive ability of the derived model ($Q^2 > 0.5$ considered as good and $Q^2 > 0.9$ as excellent). To further evaluate the predictive power of the robust OPLS-DA model, 80% of samples were applied to construct a model, which was used to predict the remaining 20% of samples. The variable importance in the projection (VIP) values of all peaks from OPLS-DA models was taken as a coefficient for peak selection. The VIP value was represented by a unitless number, where higher values suggested greater discriminatory power of the metabolite. Those variables with VIP > 1 were considered potential biomarker candidates for group discrimination.

**Statistical analysis**

The relative concentrations of those metabolites with VIP > 1 were calculated by integrating the signals in the spectra. Statistical significance was assessed using the Mann–Whitney $U$ test, and $P < 0.05$ was considered statistically significant. The relative concentrations of those metabolites with VIP > 1 were calculated by integrating the signals in the spectra, and data are presented as the mean fold difference in EC metabolite abundance compared to controls. To further evaluate the diagnostic power of the potential biomarkers whose levels significantly differed between experimental groups, receiver operating characteristic (ROC) analysis in SPSS version 16.0 was performed, and the optimal area under the ROC curve (AUROC), specificity and sensitivity of the metabolites were calculated, where AUROC > 0.8 indicated excellent diagnostic ability. Pearson correlation analysis was used to assess the association of biomarker candidates between urine and tumor tissues of EC patients with an OPLS-DA model using a correlation coefficient cut-off of $|r|$ and correlation significance of $P < 0.05$. Correlation coefficients ranged from 1.0 (maximum positive correlation) to −1.0 (maximum anticorrelation), with a value of 0 representing no correlation. Correspondingly, $|r| > 0.44$ (calculated for the sample size of 20) was considered to be a statistically significant relationship between the two metabolites.

**RESULTS**

**Metabolic profiles of esophageal tissues and urine samples**

Representative 1D $^1$H-NMR spectra of urine specimens acquired from EC patients, HCs and patient-matched esophageal tissue extracts are shown in Figure 1A and B. The standard 1D spectrum gave an overview of all metabolites. The major metabolites in the spectra were identified according to previous studies[17,18] and the Human Metabolome Database (http://www.hmdb.ca/). In all urine and esophageal tissue spectra, the aliphatic region at 0.8–4.2 ppm included numerous signals from the following water-soluble metabolites: Glutamate, glutamine, acetoacetate, citrate, cisaconitate, choline, creatine, creatinine and glycine, which are known to be involved in many biochemical processes, especially in energy metabolism.

Good discrimination between EC patients and HCs was achieved by an OPLS-DA scores plot generated from $^1$H-NMR spectra of urine specimens (Figure 2A-a). The predictive ability of the model was calculated by internal validation ($R^2 = 0.902$, $Q^2 = 0.682$, CV-ANONA $P < 0.01$), suggesting that the model possessed a satisfactory fit with good predictive power. In order to evaluate the robustness of the OPLS-DA model described above, a random permutation test was performed 400 times to further evaluate the robustness of this model, as exhibited by the steep $R^2$ and $Q^2$ regression lines and difference between $R^2$ and $Q^2$ ($R^2 = 0.886$ and $Q^2 = 0.660$), indicating that this was an excellent model suitable for data analysis (Figure 2A-b). To further assess the predictive ability of the model for unknown samples, we randomly selected 80% of urine samples (“training set”, 33 EC patients and 32 HCs) to construct an OPLS-DA model, which was then used to predict the remaining 20% of samples (“testing set”, 8 EC patients and 8 HCs). As can be seen in Figure 2A-c, the testing sets of EC patients and HCs were correctly located in their corresponding region of the training sets. Urine metabolites that met the following conditions were considered potential metabolite biomarkers for EC detection: Levels of metabolites with VIP > 1 and the presence of a significant difference ($P < 0.01$) between metabolite levels of EC patients and HCs according to the Mann–Whitney $U$ test. A total of ten urine metabolites were found to be significantly changed in EC patients compared to HCs (Table 2), including higher levels of acetoacetate, cis-aconitate, citrate and glutamate, together with lower amounts of glycine, taurine, creatinine, ethanolamine, glucose and hippurate.

Tissue profiles from EC tumor tissues and their corresponding adjacent noncancerous tissues were clearly separated using the OPLS-DA scores plot (Figure 2B-a). The relative concentrations of those metabolites with VIP > 1 were calculated by integrating the signals in the spectra. Statistical significance was assessed using the Mann–Whitney $U$ test, and $P < 0.05$ was considered statistically significant. The relative concentrations of those metabolites with VIP > 1 were calculated by integrating the signals in the spectra, and data are presented as the mean fold difference in EC metabolite abundance compared to controls. To further evaluate the diagnostic power of the potential biomarkers whose levels significantly differed between experimental groups, receiver operating characteristic (ROC) analysis in SPSS version 16.0 was performed, and the optimal area under the ROC curve (AUROC), specificity and sensitivity of the metabolites were calculated, where AUROC > 0.8 indicated excellent diagnostic ability. Pearson correlation analysis was used to assess the association of biomarker candidates between urine and tumor tissues of EC patients with an OPLS-DA model using a correlation coefficient cut-off of $|r|$ and correlation significance of $P < 0.05$. Correlation coefficients ranged from 1.0 (maximum positive correlation) to −1.0 (maximum anticorrelation), with a value of 0 representing no correlation. Correspondingly, $|r| > 0.44$ (calculated for the sample size of 20) was considered to be a statistically significant relationship between the two metabolites.

**RESULTS**

**Metabolic profiles of esophageal tissues and urine samples**

Representative 1D $^1$H-NMR spectra of urine specimens acquired from EC patients, HCs and patient-matched esophageal tissue extracts are shown in Figure 1A and B. The standard 1D spectrum gave an overview of all metabolites. The major metabolites in the spectra were identified according to previous studies[17,18] and the Human Metabolome Database (http://www.hmdb.ca/). In all urine and esophageal tissue spectra, the aliphatic region at 0.8–4.2 ppm included numerous signals from the following water-soluble metabolites: Glutamate, glutamine, acetoacetate, citrate, cisaconitate, choline, creatine, creatinine and glycine, which are known to be involved in many biochemical processes, especially in energy metabolism.

Good discrimination between EC patients and HCs was achieved by an OPLS-DA scores plot generated from $^1$H-NMR spectra of urine specimens (Figure 2A-a). The predictive ability of the model was calculated by internal validation ($R^2 = 0.902$, $Q^2 = 0.682$, CV-ANONA $P < 0.01$), suggesting that the model possessed a satisfactory fit with good predictive power. In order to evaluate the robustness of the OPLS-DA model described above, a random permutation test was performed 400 times to further evaluate the robustness of this model, as exhibited by the steep $R^2$ and $Q^2$ regression lines and difference between $R^2$ and $Q^2$ ($R^2 = 0.886$ and $Q^2 = 0.660$), indicating that this was an excellent model suitable for data analysis (Figure 2A-b). To further assess the predictive ability of the model for unknown samples, we randomly selected 80% of urine samples (“training set”, 33 EC patients and 32 HCs) to construct an OPLS-DA model, which was then used to predict the remaining 20% of samples (“testing set”, 8 EC patients and 8 HCs). As can be seen in Figure 2A-c, the testing sets of EC patients and HCs were correctly located in their corresponding region of the training sets. Urine metabolites that met the following conditions were considered potential metabolite biomarkers for EC detection: Levels of metabolites with VIP > 1 and the presence of a significant difference ($P < 0.01$) between metabolite levels of EC patients and HCs according to the Mann–Whitney $U$ test. A total of ten urine metabolites were found to be significantly changed in EC patients compared to HCs (Table 2), including higher levels of acetoacetate, cis-aconitate, citrate and glutamate, together with lower amounts of glycine, taurine, creatinine, ethanolamine, glucose and hippurate.

Tissue profiles from EC tumor tissues and their corresponding adjacent noncancerous tissues were clearly separated using the OPLS-DA scores plot (Figure 2B-a). The relative concentrations of those metabolites with VIP > 1 were calculated by integrating the signals in the spectra. Statistical significance was assessed using the Mann–Whitney $U$ test, and $P < 0.05$ was considered statistically significant. The relative concentrations of those metabolites with VIP > 1 were calculated by integrating the signals in the spectra, and data are presented as the mean fold difference in EC metabolite abundance compared to controls. To further evaluate the diagnostic power of the potential biomarkers whose levels significantly differed between experimental groups, receiver operating characteristic (ROC) analysis in SPSS version 16.0 was performed, and the optimal area under the ROC curve (AUROC), specificity and sensitivity of the metabolites were calculated, where AUROC > 0.8 indicated excellent diagnostic ability. Pearson correlation analysis was used to assess the association of biomarker candidates between urine and tumor tissues of EC patients with an OPLS-DA model using a correlation coefficient cut-off of $|r|$ and correlation significance of $P < 0.05$. Correlation coefficients ranged from 1.0 (maximum positive correlation) to −1.0 (maximum anticorrelation), with a value of 0 representing no correlation. Correspondingly, $|r| > 0.44$ (calculated for the sample size of 20) was considered to be a statistically significant relationship between the two metabolites.
Figure 1 Proton nuclear magnetic resonance spectra. A: 400 MHz representative urine proton nuclear magnetic resonance (1H-NMR) spectra obtained from esophageal cancer (EC) patient (a) and healthy control (b); B: Tissue 1H-NMR spectra obtained from EC tissue (c) and adjacent noncancerous tissue (d) referenced to tetradeuteriopropionate (0.0 ppm).

2B-a). Model parameters of the 400 times permutation test generated $R^2 = 0.908$ and $Q^2 = 0.842$ (Figure 2B-b). Moreover, the OPLS-DA model showed good performance for predicting the unknown samples (Figure 2B-c). Using these criteria (VIP > 1 and $P < 0.05$), the 15 metabolites listed in Table 3 were found to be significantly changed in EC tissues compared to their corresponding noncancerous tissues, including elevated levels of valine, leucine, alanine, acetate, citrate, succinate, choline and glutamate, as well as depleted levels of creatinine and creatine, glycine, threonine, taurine, glucose, and glutamine.

Metabolic changes that overlap across urine and EC tissues

Our parallel investigations revealed a few distinct and overlapping discriminatory metabolites between cancer tissues and urine of EC patients, including decreased levels of glucose, glycine, creatinine and taurine, together with increased levels of glutamate and citrate, as compared to their respective controls. Metabolic profiling associations between potential urine and tissue biomarkers were further analyzed, plotted as correlation heat maps color-coded by the strength of Spearman correlation coefficients (Figure 3). Changes in most potential urinary biomarkers (except glutamate, citrate and glucose) were found to be correlated with changes in most biomarker candidates in EC tissues (except for glycine and acetate) ($|r| > 0.44, P < 0.05$).

Comparison of diagnostic performance of potential urinary biomarkers for...
### Table 2 Potential urine biomarkers for discriminating esophageal cancer patients from healthy controls

| Metabolite      | Chemicalshift, ppm | Fold difference | AUC (95%CI)       | Related metabolic pathways                                      |
|-----------------|--------------------|-----------------|-------------------|-----------------------------------------------------------------|
| Acetoacetate    | 2.25–2.28          | 1.55 ↑          | < 0.001           | 0.745 (0.636–0.836) Fatty acid metabolism, TCA cycle            |
| Glutamate       | 2.04–2.06          | 1.22 ↑          | 0.002             | 0.702 (0.590–0.798) Glutaminolysis, TCA cycle                  |
| Cis-aconitate   | 3.40–3.46          | 1.30 ↑          | 0.001             | 0.719 (0.608–0.813) TCA cycle, glyoxylate and dicarboxylate metabolism |
| Citrate         | 2.48–2.54 2.64–2.66| 1.27 ↑          | 0.002             | 0.643 (0.528–0.746) TCA cycle                                  |
| Hippurate       | 7.51–7.56 7.60–7.65| 0.45 ↓          | 0.002             | 0.702 (0.591–0.799) Gut microflora metabolism                  |
| Ethanolamine    | 3.08–3.16          | 0.86 ↓          | 0.001             | 0.723 (0.613–0.817) Fatty acid metabolism                      |
| Glycine         | 3.54–3.55          | 0.85 ↓          | 0.003             | 0.633 (0.518–0.737) Amino acid metabolism                      |
| Creatinine      | 3.03–3.06 4.05–4.10| 0.95 ↓          | < 0.001           | 0.790 (0.685–0.872) Urea metabolism, Creatinine metabolism     |
| Taurine         | 3.26–3.28          | 0.53 ↓          | < 0.001           | 0.763 (0.655–0.850) Amino acid metabolism                      |
| Glucose         | 3.73–3.80          | 0.89 ↓          | 0.007             | 0.694 (0.581–0.792) Glycolysis; TCA cycle                      |

EC: Esophageal cancer; HC: Healthy control; AUC: Area under the curve; TCA: Tricarboxylic acid.

**distinguishing EC**

Given that urinary glutamate, citrate and glucose in EC patients did not show correlation with esophageal tissue biomarkers, a panel of urinary metabolite markers composed of acetoacetate, cis-aconitate, hippurate, ethanolamine, glycine, creatinine and taurine was selected to compare their diagnostic performance for distinguishing EC patients from HCs. ROC analysis of the comparison of single urinary biomarkers and their combination showed that combined metabolites of the aforementioned metabolites had better diagnostic performance than any single metabolite alone in discriminating EC patients from HCs, with sensitivity, specificity and area under the curve values of 92.68%, 92.50% and 0.971, respectively (Figure 4).

**DISCUSSION**

The current study performed parallel investigations of EC tissues and adjacent noncancerous mucosal tissues alongside patient-matched urine samples to investigate how changes of the urine metabolome were linked to the changes of EC tissues metabolic phenotypes. Our study showed significant metabolic alterations in both urine and tumor tissues of EC patients compared to their respective HCs. Correlative analysis of the altered metabolites across both matrices revealed a few distinct and overlapping discriminatory metabolites, such as glucose, glycine, creatinine and taurine (decreased levels) together with glutamate and citrate (increased amounts), suggesting that EC is associated with the following dysregulated metabolic pathway perturbations, including but not limited to fatty acid metabolism, glucose and glycolytic activity, tricarboxylic acid (TCA) cycle and glutaminolysis. Metabolic profiling correlations between esophageal tissues and urine showed that most potential urine biomarkers were correlated with most of the discriminating metabolites in EC tissues, indicating that changes in urine metabolic signature could reflect reprogramming of metabolic pathways in tumor tissues, highlighting the significance of the distinct urinary metabolic profiles as potential novel and non-invasive indicators for EC detection.

Our NMR-based metabolomic findings identified distinct disturbances occurring in both tissues and urine of EC patients compared to their respective controls (Figure 5). Tumor-microenvironment cooperation may occur in cancer cells, which exhibit a high rate of anabolic metabolism, by which they take up large amounts of nutrients to fuel the TCA cycle and oxidative phosphorylation. Therefore, in order to meet the increased demands of proliferation, tumor cells display changes in energy metabolism and nutrient uptake pathways\(^\text{[19]}\). In general, tumor tissue has depleted glucose and increased citrate and succinate, the TCA intermediates, reflecting high TCA cycle activity to maintain tumor promotion\(^\text{[8,20]}\). Reduced glucose and increased citrate levels were evident in EC patient urine, further indicating enhanced glycolysis under hypoxic conditions required for rapid cancer cell proliferation\(^\text{[21,22]}\). Acetate, a source for lipid and myelin synthesis\(^\text{[13]}\), is derived from acetyl-CoA via the deacetylation of N-
acetylaspartate. The observed elevation of acetate in EC tissues might result from an increase in fatty acid metabolism, and this observation is supported by elevation of alanine derived from metabolism of pyruvate, indicating activation of glycolysis to provide higher energy needs\(^1\). Glutamine is also regarded as important for energy production in proliferating cells, and it donates nitrogen for nucleotide synthesis, resulting in the formation of glutamate (glutaminolysis). The latter can be converted to α-ketoglutarate to increase transit through the TCA cycle, providing sustainable energy required for rapid cell proliferation\(^2\). Glutamine is also regarded as important for energy production in proliferating cells, and it donates nitrogen for nucleotide synthesis, resulting in the formation of glutamate (glutaminolysis). The latter can be converted to α-ketoglutarate to increase transit through the TCA cycle, providing sustainable energy required for rapid cell proliferation\(^2\).

Increased glutamate in EC urine observed in this study could also suggest a high energy demand in proliferating cells due to augmented glutaminolysis\(^3\). Increased leucine and valine in tissues and increased acetoacetate in urine were in agreement with the ingested nutrients that fuel the TCA cycle to support cell proliferation. Similarly, cell growth and proliferation need amino acids to generate proteins required for cancer cell synthesis\(^4\), therefore leading to decreased levels of glycine and threonine in EC patients. Depleted creatine/creatinine levels in tumor tissues have been related to altered energy transfer processes and may reflect increased activity of creatine kinase, which has been previously reported to be lower in lung tumors compared to normal adjacent tissues\(^5\). Besides, creatine levels in EC patient urine samples were significantly decreased compared to HCs, which has also been reported to be lower in urine samples from colorectal cancer patients\(^6\). The observed depletion of taurine in both tissues and urine of EC patients suggest a disruption in taurine metabolism and diffusion of gut microbes associated with EC tumors\(^7\). Ethanolamine is an important fatty acid for cellular membranes\(^8\), and its decreased levels in EC urine could suggest increased consumption for biosynthesis of cellular membranes and indicate activation of fatty acid metabolism. The observed depletion of hippurate in EC urine was likely the result of gut microbiome perturbation associated with EC tumorigenesis. Hippurate is metabolized from benzoic acid, which is metabolized from the dietary polyphenol 3-hydroxyphenyl propionic acid by the gut microflora\(^9\). Choline is one of the major cell membrane phospholipids\(^10\), and is overexpressed and highly active in tumor tissues and cell lines. We observed increased choline levels in EC tissues, which was consistent with previous

Figure 2 Pattern recognitions. A: Pattern recognition of urine metabolomic profiles analyzed by proton nuclear magnetic resonance (1H-NMR) spectroscopy. (a) orthogonal partial least squares discriminant analysis (OPLS-DA) scatter plot of urine samples based on esophageal cancer (EC) patients (green dots) and healthy controls (HCs) (blue squares); (b) Statistical validation of the corresponding OPLS-DA model by permutation analysis (400 times); (c) Score plots of OPLS-DA prediction model. 80% of samples were applied to construct the model, which was used to predict the remaining 20% of samples [testing set, 8 HCs (gold diamonds); 8 EC patients (red triangles)]; B: Pattern recognition of tissue metabolomic profiles analyzed by 1H-NMR spectroscopy. (a) OPLS-DA scatter plot of EC tissue samples obtained (purple inverted triangles) and adjacent noncancerous tissue (orange pentagons); (b) Statistical validation of the corresponding OPLS-DA model by permutation analysis (400 times); (c) Score plots of OPLS-DA prediction model, with 80% of the samples applied to construct the model, which was used to predict the remaining 20% of samples [testing set, 4 EC tissues (green hexagons); 4 adjacent non-cancerous tissues (blue crosses)].
Table 3  Potential tissue biomarkers for discriminating esophageal cancer tissue from adjacent noncancerous tissue

| Metabolite | Chemical shift, ppm | Fold difference ECT / ANT | P value | AUC (95%CI) | Related metabolic pathways |
|------------|---------------------|---------------------------|---------|-------------|---------------------------|
| Valine     | 0.96–0.99 1.02–1.04 | 1.63 ↑                    | < 0.001 | 0.988 (0.889-1.000) | Amino acid metabolism |
| Leucine    | 0.93–0.95          | 1.32 ↑                    | < 0.001 | 0.852 (0.705-0.944) | Amino acid metabolism |
| Glutamate  | 1.97-2.08 2.32–2.39 | 1.30 ↑                    | < 0.001 | 0.930 (0.803-0.986) | Glutaminolysis, TCA cycle |
| Acetate    | 1.88-1.93          | 1.33 ↑                    | 0.001   | 0.790 (0.632-0.952) | SCFA metabolism |
| Alanine    | 1.43–1.48          | 1.44 ↑                    | < 0.001 | 0.920 (0.789-0.982) | Amino acid metabolism, Gluconeogenesis |
| Choline    | 3.19–3.22          | 1.59 ↑                    | < 0.001 | 0.980 (0.876-1.000) | Choline metabolism, Lipid metabolism |
| Succinate  | 2.39–2.40          | 2.12 ↑                    | 0.009   | 0.738 (0.575-0.864) | TCA cycle |
| Citrate    | 2.68–2.71          | 1.42 ↑                    | < 0.001 | 0.942 (0.820-0.991) | TCA cycle |
| Glucose    | 3.37–3.44 3.50–3.52 | 0.72 ↓                    | < 0.001 | 0.928 (0.800-0.985) | Glycolysis, TCA cycle |
| Creatinine | 3.02–3.03 4.04–4.06 | 0.64 ↓                    | < 0.001 | 0.963 (0.849-0.997) | Urea metabolism, Creatine metabolism |
| Glycine    | 3.52–3.55          | 0.75 ↓                    | < 0.001 | 0.850 (0.702-0.943) | Amino acid metabolism |
| Threonine  | 3.58–3.62          | 0.60 ↓                    | < 0.001 | 0.933 (0.806-0.987) | Amino acid metabolism |
| Creatine   | 3.90–3.94          | 0.78 ↓                    | < 0.001 | 0.917 (0.786-0.981) | Urea metabolism, Creatine metabolism |
| Glutamine  | 2.42–2.48          | 0.77 ↓                    | < 0.001 | 0.895 (0.757-0.969) | Glutaminolysis, TCA cycle |
| Taurine    | 3.24–3.28 3.33–3.34 | 0.78 ↓                    | < 0.001 | 0.878 (0.735-0.960) | Amino acid metabolism |

ACKNOWLEDGEMENTS

In addition to specific metabolite differences between tumor tissues and urine in EC patients and HCs, we also evaluated the relationships between the metabolic networks in both tissues and urine. Decreased metabolite levels of glucose, glycine, creatinine and taurine, as well as increased citrate and glutamate in EC tissues, were also detectable in the urine of EC patients. These distinct and overlapping metabolites may reflect tumor cell shedding and represent metabolic pathway aberrations across both matrices. This potentially reveals linkages to disturbances of fatty acid metabolism, glucose and glycolytic activity, TCA cycle and glutaminolysis associated with tumor proliferation. Correlative analysis of metabolic profiling between EC tissues and urine showed that changes in most potential urinary biomarkers were correlated with changes in most biomarker candidates in EC tissues, implying enhanced energy production required for rapid cell proliferation. Creatinine was found to be the most sensitive predictor of EC in urine metabolite, with an AUC of 0.790. Overall, these associations provide evidence of distinct metabolic signatures and pathway disturbances across both matrices, and changes in urinary metabolic signature could reflect the EC tissue microenvironment.

In conclusion, our parallel investigations of EC patients through 1H-NMR metabolomics revealed a great number of altered metabolites and metabolic pathway networks in EC patient urine and tumor tissues compared with HCs. We identified a few overlapping discriminatory metabolites across both matrices, derived from fatty acid metabolism (taurine and glycine), as well as metabolites (e.g., glucose, glutamate, citrate and creatinine) involved in glucose and glycolytic metabolism, the TCA cycle and glutaminolysis. Correlative analysis of metabolic profiling across tumor tissues and urine in EC patients showed that changes in most potential urinary biomarkers were correlated with changes in most candidate biomarkers in EC tissues, implying enhanced energy production required for rapid cell proliferation. In summary, these associations provide clear evidence of different metabolic signatures and metabolic pathway disturbances between EC tissues and urine, and changes in urinary metabolic signatures could reflect the EC tissue microenvironment. Our study highlighted the significance of the distinct urinary metabolic profile as a potential noninvasive indicator of EC detection. Further investigation is needed to validate these initial findings using larger samples and to establish the mechanism underlying EC progression.
Figure 3  Correlation heat map color-coded by the strength of Spearman correlation coefficients (r) between metabolites found to be important in tumor versus control discrimination. Cut-off values of |r| > 0.4 and P < 0.05 have been used. The metabolites used are those listed in Tables 2 and 3 (metabolites labeled with ‘*’ noted as tissue biomarkers). Red boxes indicate positive associations, and blue boxes indicate negative associations.

The authors thank Ju-Rong Yang for kindly providing us with the NMR experimental setting and Dr. Hong-Jun Luo for handling of tissue samples.
ARTICLE HIGHLIGHTS

Research background
A large number of studies have revealed changes of urinary metabolites between esophageal cancer (EC) and healthy controls (HCs), and some studies have demonstrated a correlation between EC and perturbed urinary metabolomic profiles.

Research motivation
However, none of the previous studies has described the correlation between urine metabolite profiles and those of the tumor and adjacent colonic mucosa in the same patient. Our study revealed a significant number of altered metabolites and metabolic pathway networks in EC patient urine and tumor tissues compared with HCs.

Research objectives
Our work is the first parallel investigation of esophageal tumor tissues and adjacent normal mucosal tissues alongside patient-matched urine samples to investigate how urinary metabolic phenotypes were linked to changes in the biochemical landscape of esophageal tumors.

Research methods
All samples were detected by a Bruker AvII 400 MHz nuclear magnetic resonance spectrometer, and all spectral data were applied to pattern recognition analysis and cross-validation by SIMCA-P software. Then, statistical significance was assessed using the Mann-Whitney U test and receiver operating characteristic analysis to calculate biomarker metabolites. Finally, we employed Pearson Correlation Analysis to assess the associations of biomarker candidates between urine and tumor tissues of EC patients.

Research results
Our study revealed metabolite changes that overlapped across both metrics, including glucose, glutamate, citrate, glycine, creatinine and taurine, indicating the networks for metabolic pathway perturbations in EC. Additionally, changes in most urinary biomarkers were correlated with changes in biomarker candidates in EC tissues.

Research conclusions
Our research is the first parallel investigation to investigate how urinary metabolic phenotypes were linked to the changes in the biochemical landscape of esophageal tumors. Our study showed significant metabolic alterations in both urine and tumor tissues of EC patients compared to their respective HCs. Our research revealed a few distinct and overlapping discriminatory metabolites, suggesting that EC is associated with the following dysregulated metabolic pathway perturbations. Furthermore, the metabolic profiling correlations between esophageal tissues and urine showed that most urine potential biomarkers were correlated with most of the discriminating metabolites in EC tissues, indicating that changes in the urine metabolic signature could reflect reprogramming of metabolic pathways in tumor tissue, highlighting the significance of the distinct urinary metabolic profiles as potential novel and non-invasive indicators for EC detection.

Research perspectives
With experiences in our study, we realized that many metabolites have associations in samples of cancer patients. In our same group, we are now investigating the serum samples of EC patients.

REFERENCES
1. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray F. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 2015; 136: E359-E386 [PMID: 25220842 DOI: 10.1002/ijc.29210]
2. Lindon JC, Nicholson JK, Holmes E, Everett JR. Metabonomics: metabolic processes studied by NMR spectroscopy of biofluids. Magnetic Resonance in Biomedicine 2015; 12: 289-320 [DOI: 10.1002/1099-0534(2000)12:5-289::AID-CMR3-3.0.CO;2-W]
3. Griffin JL, Atherton H, Shockcor J, Azorzi L. Metabolomics as a tool for cardiac research. Nat Rev Cardiol 2011; 8: 630-643 [PMID: 21931361 DOI: 10.1038/nrcardio.2011.138]
4. Lin Y, Stephenson MC, Xin L, Napolitano A, Morris PG. Investigating the metabolic changes due to visual stimulation using functional proton magnetic resonance spectroscopy at 7 T. J Cereb Blood Flow Metab 2012; 32: 1484-1495 [PMID: 22434076 DOI: 10.1038/jcbfm.2012.33]
5. Duarte IF, Gil AM. Metabolic signatures of cancer unveiled by NMR spectroscopy of human biofluids. Prog Nucl Magn Reson Spectrosc 2012; 62: 51-74 [PMID: 22364616 DOI: 10.1016/j.pnmrs.2011.11.002]
6. Lin Y, Ma C, Liu C, Wang Z, Yang J, Liu X, Shen Z, Wu R. NMR-based fecal metabolomics fingerprinting as predictors of earlier diagnosis in patients with colorectal cancer. Oncotarget 2016; 7: 29454-29464 [PMID: 27107423 DOI: 10.18632/oncotarget.7862]
7. Wang Z, Lin Y, Liang J, Huang Y, Ma C, Liu X, Yang J. NMR-based metabolomic techniques identify potential urinary biomarkers for early colorectal cancer detection. Oncotarget 2017; 8: 105819-105831 [PMID: 29285295 DOI: 10.18632/oncotarget.22402]
8. Lin Y, Ma C, Bezabeh T, Wang Z, Liang J, Huang Y, Zhao J, Liu X, Ye W, Tang W, Ouyang T, Wu R. 1 H NMR-based metabolomics reveal overlapping discriminatory metabolites and metabolic pathway disturbances between colorectal tumor tissues and fecal samples. Int J Cancer 2019 [PMID: 30720869 DOI: 10.1002/ijc.32193]
9. Nicholson JK, Lindon JC. Systems biology: Metabonomics. Nature 2008; 455: 1054-1056 [PMID: 18949495 DOI: 10.1038/4551054a]
10. Rocha CM, Carrola J, Barros AS, Gil AM, Goodfellow BJ, Carreira IM, Bernardo J, Gomes A, Sousa V, Carvalho L, Duarte IF. Metabolic signatures of lung cancer in biofluids: NMR-based metabolomics of blood plasma. J Proteome Res 2011; 10: 4314-4324 [PMID: 21784875 DOI: 10.1021/pr200550p]
11. Theodorescu D, Wittek S, Ross MM, Walden M, Conaway M, Just I, Mischak H, Feier D, HF. Discovery and validation of new protein biomarkers for urothelial cancer: a prospective analysis. Lancet Oncol 2006; 7: 230-240 [PMID: 16181332 DOI: 10.1016/S1470-2045(06)70584-8]
12. M’Koma AE, Blum DL, Norris JL, Koyama T, Billheimer D, Motley S, Ghiassi M, Ferdowski N, Bhowmick I, Chang SS, Fowke JH, Capiroli RM, Bhowmick NA, Detection of pre-neoplastic and neoplastic prostate disease by MALDI profiling of urine. Biochem Biophys Res Commun 2007; 353: 829-834 [PMID: 17194448 DOI: 10.1016/j.bbrc.2006.12.111]
13. Theodorescu D, Schiffer E, Bauer HW, Douwes F, Eichhorn F, Polley R, Schmidt T, Schöfer W, Zürbig F, Good DM, Coon JJ, Mischak H. Discovery and validation of urinary biomarkers for prostate cancer.
Liang JH et al. NMR-based metabolomics in esophageal carcinoma

*Proteomics Clin Appl* 2008; 2: 556-570 [PMID: 19759844 DOI: 10.1002/prca.200700032]

14 Pisitkun T, Johnstone R, Knepper MA. Discovery of urinary biomarkers. *Mol Cell Proteomics* 2006; 5: 1760-1771 [PMID: 16837576 DOI: 10.1074/mcp.M600008-MCP200]

15 Hasim A, Ma H, Mamtimin B, Abudula A, Niyaz M, Zhang LW, Anwer J, Sheyhidin I. Revealing the metabonomic variation of EC using ¹H-NMR spectroscopy and its association with the clinicopathological characteristics. *Mol Biol Rep* 2012; 39: 8955-8964 [PMID: 22736106 DOI: 10.1007/s11033-012-1764-z]

16 Davis VW, Schiller DE, Eurich D, Sawyer MB. Urinary metabolomic signature of esophageal cancer and Barrett's esophagus. *World J Surg Oncol* 2012; 10: 271 [PMID: 23243118 DOI: 10.1186/1477-7819-10-271]

17 Wishart DS, Jewison T, Guo AC, Wilson MR, Knox C, Bjorndahl TC, Krishnamurthy R, Saleem F, Liu P, Dame ZT, Poelzer J, Huynh J, Yallou FS, Psychogios N, Dong E, Bogumil R, Roehring C, Wishart DS. The human urine metabolome. *PLoS One* 2013; 8: e73076 [PMID: 24023812 DOI: 10.1371/journal.pone.0073076]

18 Echeverry G, Hortin GL, Rai AJ. Introduction to urinalysis: historical perspectives and clinical application. *Methods Mol Biol* 2010; 641: 1-12 [PMID: 19270154 DOI: 10.1007/1-60761-711-2_1]

19 Phelps TJ, Suflita JM, Little B. Carbon dioxide corrosion and acetate: a hypothesis on the influence of microorganisms. *Corrosion Houston Tx* 2012; 64: 854-859 [DOI: 10.5006/1.3279919]

20 Curthoys NP, Watford M. Regulation of glutaminase activity and glutamine metabolism. *Annu Rev Nutr* 2013; 33: 133-159 [PMID: 19460998 DOI: 10.1146/annurev.nutr.091412.093736]

21 Nicholson JK, Holmes E, Wilson ID. Gut microorganisms, mammalian metabolism and personalized health care. *Nat Rev Microbiol* 2005; 3: 431-438 [PMID: 15821725 DOI: 10.1038/nrmicro1522]

22 Pun WK, Chow SP, Fang D, Cheng CL, Leong JC, Ng C. Post-traumatic oedema of the foot after tibial fracture. *Injury* 1989; 20: 232-235 [PMID: 2592102 DOI: 10.1586/14737159.2015.1039515]

23 Locasale JW. Serine, glycine and one-carbon units: cancer metabolism in full circle. *Nat Rev Cancer* 2013; 13: 572-583 [PMID: 23822983 DOI: 10.1038/nrc3557]

24 Joseph J, Cardesa A, Carreras J. Creatine kinase activity and isoenzymes in lung, colon and liver carcinomas. *Br J Cancer* 1997; 76: 600-605 [PMID: 9303358]

25 van Stijn MF, Vermeulen MA, Siroen MP, Wong LN, van den Tol MP, Ligters-Melis GC, Houdijk AP, van Leeuwen PA. Human taurine metabolism: fluxes and fractional extraction rates of the gut, liver, and kidneys. *Metabolism* 2012; 61: 1036-1040 [PMID: 22304837 DOI: 10.1016/j.metabol.2011.12.005]

26 Amelio I, Cutruzzolà F, Antonov A, Agostini M, Melino G. Serine and glycine metabolism in cancer. *Trends Biochem Sci* 2014; 39: 191-198 [PMID: 24657017 DOI: 10.1016/j.tibs.2014.02.004]

27 Nicholson JK, Holmes E, Wilson ID. Gut microorganisms, mammalian metabolism and personalized health care. *Nat Rev Microbiol* 2005; 3: 431-438 [PMID: 15821725 DOI: 10.1038/nrmicro1522]

28 Pun WK, Chow SP, Fang D, Cheng CL, Leong JC, Ng C. Post-traumatic oedema of the foot after tibial fracture. *Injury* 1989; 20: 232-235 [PMID: 2592102 DOI: 10.1586/14737159.2015.1039515]
